ERBB2 and pancreatic neoplasm: Specifically, studies have reported the over-expression of EGFR and HER-2 in patient pancreatic cancer tissue (45–95% and 43–69%, respectively) [60,97] and patient head and neck squamous cell carcinoma tissue (up to 90% and 68%, respectively) [25,98,99].